Lilly intends to bolster outcomes in patients with cardiometabolic conditions through the Versanis takeover. Credit: Jonathan Weiss / Shutterstock.com.

Eli Lilly and Company has signed an agreement for the acquisition of clinical-stage biopharmaceutical firm Versanis Bio in a $1.925bn deal.

Versanis shareholders will receive the total amount in cash, including upfront development and sales-based milestone payments. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Established by Aditum Bio in 2021, Versanis develops new therapies for treating cardiometabolic ailments.

Its lead asset, bimagrumab, is currently being evaluated in the Phase IIb BELIEVE clinical trial both as a monotherapy and along with semaglutide in adults who are obese or overweight. 

Bimagrumab is a monoclonal antibody that attaches to activin type II A and B receptors, hindering activin and myostatin signalling. 

See Also:

Eli Lilly and Company diabetes, obesity and cardiometabolic research group vice-president Ruth Gimeno stated: “Lilly is committed to investigating potential new medicines to fight cardiometabolic diseases, including obesity, a chronic disease that affects over 100 million Americans. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“By unifying the knowledge and expertise in incretin biology at Lilly with the deep understanding of activin biology at Versanis, we aim to harness the potential benefits of such combinations for patients.”

The transaction between Lilly and Versanis is subject to customary closing conditions.

The latest development comes after Lilly agreed to acquire all outstanding shares in Sigilon Therapeutics for $309.6m.